Abstract:AIM:To evaluate the clinical efficacy and safety of technetium-99 methylene diphosphate(99Tc - MDP)with glucocorticoid therapy for Graves ophthalmopathy.
METHODS:A total of 96 patients with Graves ophthalmopathy were randomly divided into two groups, The control group assigned to receive methylprednisolone injection pulse therapy and oral prednisone tablets in the intermittent period. The experimental group was given the treatment of 99Tc - MDP injection based on therapy of the control group. Then the clinical efficacy and safety of the two therapies were compared.
RESULTS:The clinical symptoms of the two groups were improved. The efficiency rate of the experimental group was higher than that of the control group, especially on the degree of exophthalmos, and the difference was statistically significant(P<0.05). The activity of Graves ophthalmopathy had been improved in the two groups, with no significant difference(P>0.05). The experimental group did not have serious adverse reactions associated with 99Tc-MDP.
CONCLUSION:There are obvious improvements in patients with Graves ophthalmopathy treated by 99Tc - MDP combined with glucocorticoid, especially in the degree of exophthalmus and with less adverse reactions, which deserves promotion.
